S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:ARAY

Accuray (ARAY) Stock Price, News & Analysis

$2.14
-0.07 (-3.17%)
(As of 04/19/2024 ET)
Today's Range
$2.10
$2.22
50-Day Range
$2.14
$2.90
52-Week Range
$2.10
$4.30
Volume
634,097 shs
Average Volume
481,101 shs
Market Capitalization
$212.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

Accuray MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
285.5% Upside
$8.25 Price Target
Short Interest
Bearish
5.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.63mentions of Accuray in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.07) to $0.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

234th out of 909 stocks

Surgical & Medical Instruments Industry

29th out of 97 stocks

ARAY stock logo

About Accuray Stock (NASDAQ:ARAY)

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

ARAY Stock Price History

ARAY Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
ARAY Apr 2024 4.000 call
7 Screaming Stock Buys for Under $5
ARAY Mar 2024 2.000 call
ARAY Mar 2024 2.000 put
See More Headlines
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ARAY
CUSIP
00439710
Employees
1,024
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$8.25
High Stock Price Target
$9.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+285.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-9,280,000.00
Pretax Margin
-2.38%

Debt

Sales & Book Value

Annual Sales
$447.61 million
Book Value
$0.56 per share

Miscellaneous

Free Float
95,420,000
Market Cap
$212.22 million
Optionable
Optionable
Beta
1.44

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


ARAY Stock Analysis - Frequently Asked Questions

Should I buy or sell Accuray stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARAY shares.
View ARAY analyst ratings
or view top-rated stocks.

What is Accuray's stock price target for 2024?

3 analysts have issued 12 month price objectives for Accuray's shares. Their ARAY share price targets range from $7.50 to $9.00. On average, they expect the company's share price to reach $8.25 in the next year. This suggests a possible upside of 285.5% from the stock's current price.
View analysts price targets for ARAY
or view top-rated stocks among Wall Street analysts.

How have ARAY shares performed in 2024?

Accuray's stock was trading at $2.83 at the beginning of 2024. Since then, ARAY stock has decreased by 24.4% and is now trading at $2.14.
View the best growth stocks for 2024 here
.

When is Accuray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ARAY earnings forecast
.

How can I listen to Accuray's earnings call?

Accuray will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "2071766".

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings data on Wednesday, January, 31st. The medical equipment provider reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.05. The medical equipment provider earned $107.24 million during the quarter, compared to analysts' expectations of $107.11 million. Accuray had a negative trailing twelve-month return on equity of 28.11% and a negative net margin of 3.25%. During the same period in the prior year, the firm posted ($0.02) EPS.

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2024 earnings guidance on Wednesday, January, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $460.0 million-$470.0 million, compared to the consensus revenue estimate of $463.0 million.

What is Joshua Levine's approval rating as Accuray's CEO?

107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

Who are Accuray's major shareholders?

Accuray's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kovack Advisors Inc. (1.09%), Silverberg Bernstein Capital Management LLC (0.42%) and Bridge City Capital LLC (0.12%). Insiders that own company stock include Ali Pervaiz, Brandon W Green, Byron C Scott, Gina Corradetti, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Sandeep Chalke and Suzanne C Winter.
View institutional ownership trends
.

How do I buy shares of Accuray?

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Accuray have any subsidiaries?
The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.
Read More
This page (NASDAQ:ARAY) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners